MBS-303

N/A

Report date: 2026/03/19 17:01:17

Base Information

Drug NameMBS-303
Drug Alias NameMBS-303MSC-303MSB-303
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-CD20
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20
Therapy Area/IndicationsNephrotic SyndromeLupus NephritisGlomerulonephritis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Mabworks Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Tianguangshi Pharmaceutical Technology Co LtdShanghai Changzheng HospitalBeijing Mabworks Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsNephrotic SyndromeLupus NephritisGlomerulonephritis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A